Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis
- 15 January 2002
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 109 (2) , 285-286
- https://doi.org/10.1172/jci14891
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cancer gene therapy using a survivin mutant adenovirusJournal of Clinical Investigation, 2001
- Cancer gene therapy using a survivin mutant adenovirusJournal of Clinical Investigation, 2001
- The Survivin saga goes in vivoJournal of Clinical Investigation, 2001
- Inhibition of melanoma tumor growth in vivo by survivin targetingProceedings of the National Academy of Sciences, 2001
- Inhibition of melanoma tumor growth in vivo by survivin targetingProceedings of the National Academy of Sciences, 2001
- Expression of survivin and Bcl-2 in the normal human endometriumMolecular Human Reproduction, 2000
- Analysis of human transcriptomesNature Genetics, 1999
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.1999
- Expression of the Novel Inhibitor of Apoptosis Survivin in Normal and Neoplastic SkinJournal of Investigative Dermatology, 1999